Achieving glycemic goals in type 2 diabetes
There is increasing evidence that the majority of individuals with diabetes are not treated to currently recommended glycemic goals. Rubino et al. (abstract 324) analyzed a U.K. database of 31,289 individuals with type 2 diabetes, of whom 2,501 had not received insulin and had A1C Ͼ8% despite treatment with two oral hypoglycemic agents (abstract numbers refer to the ADA Scientific Sessions, Diabetes 55 [Suppl. 1], 2006). After 1.8 years, 25% had started insulin; 4.9 years elapsed before half had started insulin, with similar lack of rapidity of treatment intensification among those diagnosed with retinopathy (18%) or neuropathy (7%). With A1C thresholds of 7 and 9%, half had started insulin at 6.3 and 4.2 years, respectively. Similarly, Nichols et al. (abstract 535) identified 4,365 individuals from the Kaiser Permanente Northwest pharmacy records starting sulfonylurea plus metformin, with a mean A1C 8.4%, and 79 and 51% of patients achieving A1C Ͻ8% and Ͻ7%, respectively. Sixty-six percent of the former group rose to Ͼ8% (after a mean of 16 months), and 75% of the latter group rose to Ͼ7% (mean of 11 months), with 73% not receiving insulin over 33 months of follow-up. Those whose A1C initially fell below 7% ultimately receiving insulin had mean A1C 9.2% when this treatment was added, at a mean of 28 months. Riedel and Plauschinat (abstracts 552 and 553) assessed treatment patterns of 9,416 type 2 diabetic individuals initiated on oral agents (mean A1C 8.4%), the twothirds whose baseline A1C was Ն7% with mean A1C 9.5%. An additional treatment was added at 8 months, with mean A1C 8.5%, although half of those receiving an additional oral agent did not have repeat A1C testing, a factor which the authors speculate might contribute to delayed therapy intensification. Only 31% of those receiving an oral hypoglycemic agent achieved A1C Ͻ7%, and 39% of these individuals subsequently had A1C rising to Ն7% over a mean of 18 months. Comparing 5,453 individuals started on metformin, 2,373 with a sulfonylurea, and 1,590 with a thiazolidinedione (TZD), treatment failure was more likely with a sulfonylurea than with metformin, with a trend to lowest treatment failure rates with a TZD.
Considerations for use of insulin in treatment of type 2 diabetes
In context of these findings, a symposium on approaches to treatment of type 2 diabetic individuals failing to achieve adequate glycemic control with oral agents gave a number of important insights. Matthew Riddle, Portland, Oregon, discussed the use of basal insulin, noting that a patient with an A1C of ϳ9% will have a 24-h glucose pattern with a relatively constant increase in glucose levels through the day from the pattern exhibited by a diabetic patient under better control, so that at least half of the patient's "glycemic burden" will reflect increased basal glycemia. This person's treatment, Riddle concluded, requires provision of basal insulin, lowering fasting glucose levels, and consequently downward shifting the overall pattern of hyperglycemia. Less optimal, from this perspective, would be a premixed insulin, while neither prandial insulin nor exenatide, which lowers postprandial glycemia in particular, would be appropriate alone in this formulation. Portal insulin is the main regulator of glucose production, but systemic insulin, by suppressing free fatty acid (FFA) release, further indirectly reduces glucose production. Injected insulin augments both portal and systemic insulin, effectively suppressing basal glucose overproduction. Further, Riddle stated that replacing basal insulin reduces hypertriglyceridemia, improves HDL cholesterol, improves vasodilation, suppresses inflammatory markers, improves myocardial metabolism under stress, and reduces mortality in the intensive care unit. Endotheliumdependent vasodilation improves after starting basal insulin (1) and plasma markers of inflammation are suppressed, particularly in individuals with both diabetes and metabolic syndrome. In individuals having coronary artery bypass graft surgery, infusion of glucose, insulin, and potassium decreases plasma FFA and ␤-hydroxybutyrate, improving myocardial function (2), a finding that Riddle suggested could be extrapolated to longer-term effects of basal insulin administration.
Riddle described a trial comparing the basal insulins glargine and NPH, terming it a "proof of principle" study of the concept that aggressive algorithmbased approaches can effectively lower glycemia (3). Enrolled type 2 diabetic individuals inadequately controlled on oral agents were set a 100 mg/dl fasting glucose goal. Of 367 individuals randomized to glargine and 389 to NPH, 90% received a sulfonylurea, 83% metformin, and 10% a TZD. Enrolled individuals received 2, 4, 6, or 8 units insulin at bedtime, initially based on fasting glucose 100 -120, 120 -140, 140 -180, or Ͼ180 mg/dl, respectively, with titration every 2 days based on the mean glucose using the same schedule of increments. A glycemic plateau began to be seen between 8 and 12 weeks. Little severe hypoglycemia was seen, but mildto-moderate hypoglycemia did occur, with nocturnal glucose (documented Յ72 mg/dl) in 27% of those receiving insulin glargine and in 33% of those receiving NPH. Riddle commented that postprandial glucose increments limit achievement of A1C Ͻ7% with this approach, citing a similarly designed Finni s h s t u d y o f m e t f o r m i n -t r e a t e d individuals randomized to the addition of NPH or glargine insulin, with fasting blood glucose titrated to 100 -105 mg/dl. After 9 months, A1C levels were 7.1-7.2%, despite achievement of the fasting glucose goal, in association with elevated glucose levels after breakfast and dinner (4) . Potential approaches for further normalization of glycemia would include switching to multiple doses of a premixed insulin, adding exenatide, or adding premeal rapid-acting insulin, with Riddle suggesting the latter to be the best approach. He reviewed a study comparing lispro 75/25 with human NPH/regular 70/30, without oral agents, in which A1C averaged 8% and fasting glucose exceeded 150 mg/dl. Hypoglycemia was particularly seen before lunch, suggesting that the premixed insulin regimens may not be desirable for achieving close glycemic control. In a study comparing premixed 70/30 twice daily without oral agents with glargine plus oral agents, the latter led to better glycemia, although with waning of glycemic control in the late afternoon (5) . Although a comparison of metformin combined with aspart 70/30 twice daily versus glargine once daily showed the former to be associated with improved glycemia, there was a glucose nadir with the premixed insulin in the late morning, and this group had greater weight gain (6); Riddle interpreted to suggest that this approach results in "defensive eating" at lunch. Riddle noted that both insulin detemir and NPH twice daily with oral agents should be considered, suggesting that these approaches lead to similar fasting glucose and somewhat better A1C than that seen with either glargine or NPH once daily (7) . He concluded that using treat-to-target basal insulin is a promising initial approach but may not suffice for achieving optimal glycemia, that premixed insulin also has undesirable characteristics, that exenatide plus basal insulin is promising, and that the use of a basal-bolus insulin approach may be ideal, although one must take into account the intensive physician-patient interaction required for such treatment. Food intake varies greatly, he noted, suggesting that a potential approach is to titrate to optimal fasting glucose with basal insulin and then add a rapid-acting analog before the main meal of the day, titrating to a subsequent preprandial (or bedtime) glucose of ϳ120 mg/dl. He suggested that such an approach allows the type 2 diabetes patient with A1C 9% on oral agents to achieve a fasting glucose of 105 mg/dl and an A1C of 6.6%.
Philip Raskin, Dallas, Texas, gave a somewhat different view of approaches with mixed insulin, suggesting that this is a clinically useful approach. He reviewed the treatment goals of A1C Ͻ6.5 to 7%, noting that because of progressive ␤-cell failure, oral hypoglycemic agents are not completely effective for many patients, leading to the need for insulin treatment. Raskin suggested that the "right way to treat diabetes is combination therapy with insulin and oral agents" to improve insulin sensitivity. He described a study of 43 individuals with insulin-treated type 2 diabetes receiving metformin or placebo and Ͼ50 units insulin/day, with an A1C goal Ͻ5.6% (8) . With insulin alone, A1C decreased from 9.1 to 7.5%, while those patients receiving insulin with metformin showed a fall from 9 to 6.5%. A1C Ͻ7% was achieved by 41 versus 59%, with 54% of those receiving combination treatment reaching an A1C Ͻ6.5%. Furthermore, the metformin plus insulin group required a less complicated treatment schedule, with many of these patients controlled with human 70/30 insulin twice daily. Raskin pointed out that there was no weight gain in the metformin group, while those receiving insulin alone gained 3 kg. In a study of 28 individuals receiving insulin with metformin, or insulin with troglitazone, and subsequently given both sensitizers with continued insulin administration, Raskin showed evidence suggesting that the TZD combination with insulin more effectively lowered glucose levels than that with metformin, with administration of both sensitizers with insulin leading to still better A1C levels (9) . He noted that although the TZD was more potent in glucose lowering, the approach best minimizing weight gain was to first give insulin with metformin and then to add troglitazone. Insulin is, of course, needed for individuals presenting with major hyperglycemia or for individuals with hyperglycemia despite lifestyle and maximal oral agent treatment. Raskin advised giving two daily injections of 70/30 insulin, usually with metformin, with subsequent adjustment for insulin dose/type/number of injections and the addition of a TZD to be an optimal approach. With this treatment in his clinic, A1C decreased from 10.6 to 5.8% with what he characterized as modest weight gain. Raskin recommended initiating insulin at 0.4 -0.7 units ⅐ kg Ϫ1 ⅐ day Ϫ1 and continuing metformin, and often TZDs, but discontinuing secretagogues and ␣-glucosidase inhibitors. He recommended starting with either bedtime glargine or NPH, or two daily injections of mixed insulin, changing the insulin dosing and type as required. He referred to one of the studies reviewed by Riddle, of 233 individuals with type 2 diabetes having A1C Ն8% and BMI Յ40 kg/m 2 , receiving at least 1,500 mg metformin daily, many also receiving 30 mg pioglitazone daily (6) . He showed that those receiving the mixed insulin aspart 70/30 had a 2.8% reduction in A1C, while those receiving glargine had a 2.4% reduction. Those whose baseline A1C was at least 8.5% showed a 3.1 versus 2.6% reduction, while those with baseline A1C Ͻ8% had a decrement of 1.4% regardless of whether glargine or aspart 70/30 was administered. The mixed insulin was particularly effective in reducing postprandial glucose levels, although Raskin acknowledged that more weight was gained, and hypoglycemia occurred more frequently with mixed insulin treatment. A similar study showed superior glucose lowering with premixed lispro 75/25 insulin twice daily to that with glargine in metformin-treated individuals (10). Raskin also reviewed a study in which aspart 70/30 was used starting with one dose, then advancing to two doses, and finally to three doses daily, as required for glycemic control, showing that 41, 70, and 77% achieved A1C Ͻ7%, respectively, and that 21, 52, and 60% achieved A1C Ͻ6.5%, respectively (11), leading to his conclusion that "two shots are better than one and three shots are better than two." Raskin stressed that insulin should not be used as a threat and that "it's not their fault" if a patient requires insulin; thus, one should address the understandable anxiety and sense of personal failure experienced by many individuals with diabetes who do require this treatment. Fear of hypoglycemia, fear of injections, and weight gain are additional issues, but one should emphasize the benefit of improved glycemia in reducing the risk of complications. He suggested that "70/30 is more than just a compromise. It is safe, and very effective."
Robert Ratner, Washington, DC, began a discussion of the potential benefit of exenatide by agreeing, "Insulin is a good drug. It works." There are, however, issues. Many individuals are often psychologically resistant to this treatment, and many physicians feel that initiation of insulin treatment requires overly great effort. There are issues of weight gain, hypoglycemia, inconvenience, and cost, both of the treatment itself and of the more intensive glucose monitoring required. Ratner discussed the phenomenon of physician delay in initiating or intensifying pharmacologic treatment in individuals with diabetes. There is a 3-year delay before initiation of an oral agent treatment, with a mean A1C of 8.8%, followed by a delay of Ն3 years to achieve an A1C of 9.4% before addition of a second oral agent. Again, physicians typically wait for the A1C to approach 9% before adding insulin, resulting in a further 3-year delay. Intensification of treatment with oral agents is usually only of modest benefit. In an observational report of triple oral therapy, A1C stabilized at 8% (12) . A randomized controlled trial of triple oral agent therapy reported a reduction in A1C from 9.7 to 8.5% (13), leading Ratner to comment, "starting triple oral agent therapy above nine isn't going to get you where you want to go." At lower levels of glycemia, addition of pioglitazone to a sulfonylurea plus metformin allows glycemic control comparable with that of adding an evening dose of NPH (14) . Similarly, addition of the sulfonylurea glimepiride in individuals receiving metformin with a TZD decreases A1C (15) . The question, Ratner asked, is whether it is "worth it" to add a TZD in metformin-sulfonylurea failures, rather than adding glargine, and it appears to have been answered in the affirmative. He reviewed a comparison of the two approaches showing similar A1C reduction, although neither led to a fall in mean A1C below 7% (16) . Similarly, a study comparing the combination of metformin with premixed insulin versus triple oral agent therapy showed that "insulin brought the A1C down more quickly but at six months . . . it was no better" (17) . He concluded that "the barriers to insulin therapy may actually be reasonable," but that "the difficulty is the natural history of the disease." He cited an observational study showing that half of triple oral agent-treated individuals fail to maintain glycemic control over a 6-year period (18) , leading Ratner to question, "Can we get any better?" He reviewed a study of exenatide versus placebo in type 2 diabetic individuals receiving a sulfonylurea plus metformin (19) . Those receiving exenatide had an initial A1C of 8.5%, decreasing 0.5-1.0%, and a body weight of ϳ100 kg, decreasing by 2 kg. Hypoglycemia did occur, although with progressively decreasing frequency over time as the sulfonylurea dose was reduced, suggesting a strategy of decreasing sulfonylurea to the minimal effective dose on initiation of exenatide treatment. Ratner noted that ongoing studies will address the use of exenatide with other combinations. Asking why not use insulin only, Ratner emphasized that "we still have a problem" with hypoglycemia. In a study comparing glargine with exenatide in type 2 diabetic individuals receiving oral agents, there was similar achievement of A1C Ͻ7%, but a 2-kg weight gain versus a 2-to 2.5-kg loss of weight, leading Ratner to suggest that the combination of less weight gain and less hypoglycemia makes exenatide "the logical next step," offering a simpler, equally durable, safe approach to that with insulin, while leading to minimal hypoglycemia and to weight loss. He concluded, "This is the last great hope of changing the natural history of type 2 diabetes." 
Aspects of insulin resistance
performed hyperinsulinemic-euglycemic clamp studies in 7 individuals with normal insulin sensitivity, 17 with glucose intolerance and insulin resistance, and 7 with type 2 diabetes. Mitochondrial number was 40 and 52% as great and nitric oxide production 8 and 28% as great in T lymphocytes isolated from the insulinresistant and diabetic groups, respectively (compared with the insulin-sensitive group), suggesting this to be a method that could be used in distinguishing individuals with and without insulin resistance.
Type 2 diabetes treatment by cytokine modulation
Several new approaches are being developed to improve glycemic treatment of type 2 diabetes. The proimflammatory cytokine interleukin (IL)-1 induces rodent and human ␤-cell apoptosis in vitro, and type 2 diabetes is associated with increased islet IL-1 expression. Thomas R. Mandrup-Poulsen, Gentofte, Denmark, described a study of the effect of the IL-1 receptor antagonist Anakinra (Kineret) in 64 type 2 diabetic individuals. After 13 weeks, those patients with fasting glucose Ͼ144 or A1C Ͼ8% were also given insulin to intensify treatment. A1C decreased 0.4% with treatment, while increasing 0.1% in a placebo group, with the 120-min postmeal plasma glucose increasing 1 mmol/l with placebo and decreasing 0.6 mmol/l with active treatment. Insulin sensitivity decreased in the placebo group, while remaining stable in those receiving the IL-1 antagonist, and the insulin secretory meal response decreased with placebo and increased with treatment, suggesting that the intervention had dual effects on insulin resistance and on insulin secretion. Tesauro et al. (abstract 74) found that the vasodilatory response to nitroprusside and to acetylcholine, which increases endogenous nitric oxide release from vascular endothelium, was impaired in 12 individuals with versus 12 without metabolic syndrome and that intraarterial administration of infliximab, a tumor necrosis factor-␣-neutralizing antibody, increased this vasodilatory effect, suggesting a mechanism of the endothelial dysfunction associated with insulin resistance. In an interesting study of immune insulin resistance, Nugaram et al. (abstract 605) treated an anti-nuclear antibody-positive 18-year-old man with anti-insulin receptor antibody-mediated diabetes, who failed to respond to metformin, pioglitazone, and up to 500 units daily insulin, with four weekly 375 mg/m 2 intravenous doses of the chimeric murine/human monoclonal antibody against CD20 molecule on B lymphocytes Rituximab, allowing resolution of the syndrome.
Morino et al. (abstract 6-LB) induced heat-shock protein-72, by combined mild electrical stimulation and hyperthermia in both high-fat fed and db/db mice, finding a 20% reduction in fasting glucose, a 38% decrease in fasting insulin, and a doubling of serum adiponectin and of uncoupling protein-1 mRNA expression in brown adipose tissue and with a 34 and 44% respective reduction in visceral and subcutaneous fat, reduction in adipocyte size, and improvement in fatty liver, suggesting a potential therapeutic approach for insulin-resistant states including type 2 diabetes and the metabolic syndrome. In a related study, Kolonics et al. (abstract 10-LB) studied BGP-15 (N-Gene Research Laboratories), a hydroxylamine derivative that increases heat-shock proteins and restores constitutive nitric oxide synthase activity in hyperglycemia, and was found to double insulin-stimulated glucose uptake in two animal models. In 42 nondiabetic individuals with insulin resistance given the agent for 28 days, whole-body glucose utilization similarly increased 1.6 -1.75 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 . In vitro, nitric oxide synthase and mitochondrial function improved, suggesting this to be a candidate pharmacologic insulin sensitizer.
Insulin sensitizers
A number of studies addressed issues of insulin resistance and treatment approaches to improve insulin sensitivity. Von Eynatten et al. (abstract 13-LB) reported that adipocyte-specific fatty acidbinding protein, which is increased in obese rodents in adipocytes and macrophages and appears to protect against atherosclerosis in knockout models, was elevated in individuals with diabetes and coronary artery disease, correlating with reduced insulin sensitivity and with A1C, triglycerides, C-reactive protein, and low HDL cholesterol; this suggests that it may be a useful biomarker of insulin resistance. Rendell and McGettigan (abstract 606) studied 568 type 2 diabetic men, 44% with testosterone Ͻ300 mg/dl and 54% with testosterone Ն300 mg/dl, the latter having 50% higher HOMA of insulin sensitivity, leading the authors to speculate that androgen deficiency might contribute to insulin resistance, and suggesting that testosterone might be considered another potential biomarker.
In an interesting study that may relate to the development of heart failure with TZD treatment, Son et al. (abstract 700) studied a mouse model with increased heart-specific PPAR (peroxisome proliferator-activated receptor)␥1 expression, showing no effect on systemic metabolic parameters (weight, glucose, triglyceride, or fatty acid levels) at 8 months but increased cardiac PPAR␥ target genes, including lipoprotein lipase and carnitine palmitoyltransferase-1, with increases in cardiac weight and triglyceride levels in association with development of dilated cardiomyopathy. There remain, however, intriguing studies suggesting an antiatherosclerotic benefit of these agents. Kubota et al. (abstract 138) studied mice with and without deletion of the adiponectin gene, showing that neointimal formation in response to arterial injury was increased in mice not expressing adiponectin and that pioglitazone reduced the neointimal response in both sets of animals, decreasing both inflammation and the proliferation of vascular smooth muscle, although with a delay in those lacking the ability to produce adiponectin in response to TZD. Katayama In 50 healthy subjects, adiponectin was unchanged with placebo but increased 1.7-, 3.3-, 5.3-, and 4.6-fold at 14 days in those receiving 1-, 2.5-, 5-, and 10-mg doses, without change in insulin or glucose levels. In 426 type 2 diabetic patients, placebo-adjusted fasting glucose levels decreased 13, 39, and 57 mg/dl after a 6-week period of treatment with 0.5, 2, and 5 mg rivoglitazone, while decreasing 19 mg/dl in patients receiving 30 mg pioglitazone daily. Adiponectin increased 5.1, 16.8, and 26.0 g/ml with the three rivoglitazone dosages and 7.6 g/ml with pioglitazone. Schö ndorf et al. (abstract 609) studied 675 individuals treated with pioglitazone, finding doses of 15, 30, and 45 mg daily to be associated with 2-, 2.5-, and 3-fold respective increases in adiponectin. Kang et al. (abstract 499) found that polymorphisms of the gene for perilipin, an adipocyte-specific phosphoprotein associated with the periphery of lipid storage droplets, required for lipid storage and fatty acid release (20) , correlated with weight gain in 160 type 2 diabetic individuals treated with rosiglitazone for 24 weeks; those with the AA genotype of the 1148GϾA polymorphism did not show weight gain, while GG and GA genotypes gained 1.3 and 0.9 kg, respectively. Another genetic polymorphism, the Pro12Ala variant of the PPAR␥2 gene, is associated with decreased PPAR␥ activity. Of 326 type 2 diabetic individuals, Vestergaard et al. (abstract 321) showed that 78 with the Pro12Ala genotype had less benefit from treatment with pioglitazone than the 248 individuals with the Pro12Pro genotype. Such assessment may allow better selection of candidates for a TZD. Uemura et al. (abstract 573) measured body water and fat mass in 47 type 2 diabetic individuals treated with 45 mg pioglitazone versus placebo for 8 weeks, showing that significant weight gain and increase in body fat could be demonstrated at 4 weeks but that increase in total body water began at 2 weeks, a dissociation between the two effects. Miyazaki et al. (abstract 529) treated 20 type 2 diabetic individuals with 8 mg rosiglitazone daily for 16 weeks and found a reduction in fasting glucose from 185 to 139 mg/dl, in A1C from 8.5 to 7.1%, and in FFA from 789 to 656 Eq/l, with increases in adiponectin from 6.2 to 18.2 g/ml and a 33% increase in insulin-mediated total body glucose disposal; this correlated with both improved insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation and with adiponectin. Krzyzanowska et al. (abstract 508) treated eight healthy men with 8 mg rosiglitazone daily versus placebo for 21 days, with adiponectin increasing from 5.9 to 14.3 g/ml and FFAs decreasing from 377 to 188 mol/l, while no effect on either parameter was seen in eight men given placebo. With infusion of heparin and a lipid emulsion on day 21, FFA levels increased to a lesser extent and adiponectin further increased to 18.1 g/ml with rosiglitazone. Insulin sensitivity decreased similarly in both groups, however, suggesting that the TZD-induced increase in adiponectin may not explain the insulin sensitizing effects of these agents.
TZDs may allow more sustained glycemic control than seen with sulfonylureas. Spanheimer et al. (abstract 320) treated 2,120 individuals with pioglitazone versus glyburide (with metformin if needed) for 3 years, with insulin added for A1C levels Ͼ7.5%. Baseline A1C was 9.5%, and glycemic control was comparable in the two groups for the 1st year of study, but a significantly greater decline was seen in A1C in the pioglitazone group from 72 to 156 weeks by 2-2.5 versus 1.5-2% in those randomized to glyburide. Markolf et al. (abstract 604) randomized 500 metformin-treated type 2 diabetic individuals to 30 mg pioglitazone versus 3.5 mg glyburide daily, finding that A1C decreased from a baseline of 8.5% by 1% vs. 0.6%, with 22 vs. 55% requiring insulin over the subsequent 3. reported an observational study suggesting similar effects of adding rosiglitazone and pioglitazone to a maximal-tolerated dose of metformin plus sulfonylurea treatment. At 4 months, mean A1C fell from 9.3 to 7.5 with rosiglitazone and from 9.5 to 7.4 with pioglitazone, including 65 and 62%, respectively, achieving an A1C Յ7.5%. Among responders, only 61 and 62%, respectively, maintained an A1c Յ7.5% at 1 year.
Kupfer (22) . A number of fascinating subanalyses of this study were presented at the American Diabetes Association meeting. Charbonnel and Scheen (abstract 448) discussed the long-term glycemic effects of pioglitazone versus placebo in the 1,314 individuals receiving metformin plus sulfonylurea at the beginning of the study. A1C decreased from baseline of 8% to 7.2% with pioglitazone, while decreasing to 7.8% in the placebo group, and 16% vs. 31% required additional insulin. Weight increased 4.1 kg versus decreasing 0.7 kg, and edema occurred in 29 versus 17%. The same aut h o r s ( a b s t r a c t 5 6 1 ) d e s c r i b e d characteristics of the 1,760 individuals in PROactive receiving insulin at study onset, finding insulin doses of 47 units daily in both groups at baseline and at study end 42 versus 55 units daily. A1C decreased 0.9% in individuals receiving pioglitazone, while decreasing 0.5% in those receiving placebo. Edema developed in 31 versus 18% and hypoglycemia in 41 versus 29%. Massi-Benedetti et al. (abstract 523) reported that of the 3,478 study participants not taking insulin at baseline, 183 versus 362 required insulin at study end. Increased frequency of edema and hypoglycemia with pioglitazone were again reported in this subset. Heine et al. (abstract 484) reported that 9.7 versus 10.7% of those receiving pioglitazone versus placebo had elevated ALT at baseline, with 5.9 versus 11.9% showing this abnormality at study end, suggesting an effect on NAFLD.
Wilcox and Kupfer (abstract 317) presented further analysis of the effect of pioglitazone on major adverse cardiovascular events, showing that 13% of individuals receiving pioglitazone versus 16% of those receiving placebo had death, nonfatal nonsilent myocardial infarction, nonfatal stroke, or acute coronary syndrome and that 4 versus 5% had a myocardial infarction. Of 486 versus 498 individuals in the study who had a stroke before randomization, Wilcox et al. (abstract 579) reported in a prespecified analysis that stroke occurred during follow-up in 5.6% of those receiving pioglitazone versus 10.2% of those receiving placebo, a 47% reduction. Freemantle et al. (abstract 471) used a simulation model to replicate the ϳ10% cardiovascular disease benefit shown in the PROactive study, commenting that the study was underpowered, and that Ͼ18,000 individuals would be required to demonstrate such an effect with statistical significance. Of course, as separation between the groups did not begin to be seen until ϳ18 months of the study, with mean follow-up of 34.5 months, a similar argument could be used to suggest that a 6-year study with the same number of participants would have demonstrated benefit. It is intriguing that if a principle end point similar to those described by Wilcox et al. had been chosen, the study would have been regarded as confirmedly positive.
